Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus NUZYRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus NUZYRA.
ACTICLATE CAP vs NUZYRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Omadacycline is a aminomethylcycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
200 mg intravenously once on day 1, then 100 mg IV once daily; or 200 mg orally once on day 1, then 100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal elimination half-life is approximately 17-21 hours; supports once-daily dosing.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Fecal (approximately 76%) as unchanged drug; renal (approximately 14%) as unchanged drug; biliary excretion is minimal.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic